X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs GLENMARK PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA GLENMARK PHARMA GSK PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 65.0 14.3 455.0% View Chart
P/BV x 10.4 3.8 276.7% View Chart
Dividend Yield % 1.2 0.3 378.9%  

Financials

 GSK PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
GLENMARK PHARMA
Mar-17
GSK PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838993 386.5%   
Low Rs2,637729 361.6%   
Sales per share (Unadj.) Rs354.2325.5 108.8%  
Earnings per share (Unadj.) Rs39.839.3 101.2%  
Cash flow per share (Unadj.) Rs42.948.7 88.1%  
Dividends per share (Unadj.) Rs30.002.00 1,500.0%  
Dividend yield (eoy) %0.90.2 399.0%  
Book value per share (Unadj.) Rs236.9159.2 148.8%  
Shares outstanding (eoy) m84.70282.17 30.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x9.12.6 345.5%   
Avg P/E ratio x81.421.9 371.5%  
P/CF ratio (eoy) x75.517.7 426.8%  
Price / Book Value ratio x13.75.4 252.6%  
Dividend payout %75.45.1 1,482.3%   
Avg Mkt Cap Rs m274,216242,991 112.9%   
No. of employees `0004.713.0 36.2%   
Total wages/salary Rs m4,83016,408 29.4%   
Avg. sales/employee Rs Th6,387.07,083.9 90.2%   
Avg. wages/employee Rs Th1,028.31,265.4 81.3%   
Avg. net profit/employee Rs Th717.1855.1 83.9%   
INCOME DATA
Net Sales Rs m30,00091,857 32.7%  
Other income Rs m728374 194.9%   
Total revenues Rs m30,72892,230 33.3%   
Gross profit Rs m4,19020,367 20.6%  
Depreciation Rs m2632,644 9.9%   
Interest Rs m02,373 0.0%   
Profit before tax Rs m4,65515,724 29.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m457-810 -56.5%   
Tax Rs m1,7443,827 45.6%   
Profit after tax Rs m3,36811,088 30.4%  
Gross profit margin %14.022.2 63.0%  
Effective tax rate %37.524.3 153.9%   
Net profit margin %11.212.1 93.0%  
BALANCE SHEET DATA
Current assets Rs m16,74268,746 24.4%   
Current liabilities Rs m7,20227,027 26.6%   
Net working cap to sales %31.845.4 70.0%  
Current ratio x2.32.5 91.4%  
Inventory Days Days5285 61.0%  
Debtors Days Days2196 21.8%  
Net fixed assets Rs m8,63524,132 35.8%   
Share capital Rs m847282 300.1%   
"Free" reserves Rs m19,22244,643 43.1%   
Net worth Rs m20,06944,925 44.7%   
Long term debt Rs m1045,363 0.0%   
Total assets Rs m30,038117,639 25.5%  
Interest coverage xNM7.6-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.00.8 127.9%   
Return on assets %11.211.4 98.0%  
Return on equity %16.824.7 68.0%  
Return on capital %25.519.1 133.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52856,152 0.9%   
Fx outflow Rs m7,1938,084 89.0%   
Net fx Rs m-6,66548,068 -13.9%   
CASH FLOW
From Operations Rs m2,3606,574 35.9%  
From Investments Rs m3,008-7,124 -42.2%  
From Financial Activity Rs m-5,1085,432 -94.0%  
Net Cashflow Rs m2601,992 13.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 6.9 147.8%  
FIIs % 23.8 34.4 69.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 56,727 179.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS